Company: ADPT
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001193125-25-103752
Chunk: 54

Company: Adaptive Biotechnologies Corp
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 54
---
, pursuant to which we employ him on an at-will basis. Under the agreement, Mr. Robins is eligible to participate in our broad-based benefit plans, including group health insurance and vacation programs. We are also party to an employee non-disclosure and assignment agreement with Mr. Robins, under which Mr. Robins has agreed: (1) not to compete with us for a period of one year after the termination of his employment, (2) not to solicit our employees during his employment and for a period of one year after the termination of such employment, (3) to protect our confidential and proprietary information and (4) to assign to us related intellectual property developed during the course of his employment (the “Form of Executive Non-Disclosure and Assignment Agreement”). We are also party to an executive severance agreement which details potential benefits and payments on termination or change in control.

Chief Financial Officer – Kyle Piskel

In connection with his appointment as Chief Financial Officer in April 2024, we entered into an employment agreement with Mr. Piskel, pursuant to which we employ him on an at-will basis. Under the agreement, Mr. Piskel is eligible to participate in our broad-based benefit plans, including group health insurance and vacation programs. In addition, Mr. Piskel is also party to our form of employee non-disclosure and assignment agreement, under which the signatory must agree: (1) not to solicit our employees during his employment and for a period of one year after the termination of such employment, (2) to protect our confidential and proprietary information and (3) to assign to us related intellectual property developed during the course of his employment. We are also party to an executive severance agreement which details potential benefits and payments on termination or change in control.**

<div align='center'>43</div>

Prior to his resignation in April 2024, we were party to an employment agreement with Mr. Peterson, pursuant to which we employed him on an at-willbasis. Prior to his resignation, Mr. Peterson was also party to an executive severance agreement, under which no trigger occurred and thus no severance was paid. Chief Commercial Officer, Immune Medicine – Sharon Benzeno, PhD We are party to an amended and restated employment agreement with Dr. Benzeno, pursuant to which we employ her on an at-willbasis. Under the agreement, Dr. Benzeno is eligible to participate in our broad-based benefit plans, including group health insurance and